Command Palette

Search for a command to run...

SENORES

723.15-1.23%
Market Cap
₹3,373.43 Cr
Stock P/E
57.61
ROCE
11.94%
ROE
11.78%
Book Value
₹175.31

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Senores Pharmaceuticals Ltd. shows significant growth potential but is currently overvalued compared to peers. While its long-term revenue growth is commendable, the extremely high PE ratio indicates that it may be priced for perfection. In contrast, companies like Cipla and Dr. Reddy’s Laboratories represent strong overall performers with attractive valuations and solid profitability metrics.

Key Points
  • Senores Pharmaceuticals Ltd. has the highest 3-year revenue growth at 41.12%.
  • Cipla Ltd. and Dr. Reddy's Laboratories Ltd. demonstrate strong profitability with ROE values above 16%.
  • Senores Pharmaceuticals Ltd. is significantly overvalued with a PE ratio of 875.69, while peers like Cipla and Dr. Reddy's offer more attractive valuations.
  • Mankind Pharma Ltd. shows robust growth with a revenue YoY increase of 18.12%.
  • Divi's Laboratories Ltd. is financially weak with a very high debt-to-equity ratio and declining revenue.
Top Performers
Cipla Ltd.

Strong profitability metrics and low valuation ratios.

Dr. Reddy's Laboratories Ltd.

Consistent growth and attractive valuation with a PE of 15.50.

Mankind Pharma Ltd.

High growth potential with a strong 3-year revenue increase.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.